Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Stoke Therapeutics (NasdaqGS:STOK) has changed its independent auditor from KPMG LLP to Ernst & Young LLP. The auditor transition was recently approved by the company and disclosed as a corporate governance event. The change affects future audit engagements and oversight of the company's financial reporting. Stoke Therapeutics focuses on genetic medicines, an area that continues to attract attention as new RNA and gene based approaches move through research and development. For investors watching NasdaqGS:STOK, a shift in independent auditor sits alongside clinical progress, capital needs, and regulatory milestones as a key part of the overall risk picture. Auditor changes can influence how you think about the quality and consistency of a company's financial disclosures. As Ernst & Young LLP takes on the audit role, it will be important to watch future filings, audit opinions, and any disclosed audit related matters for additional context on governance and reporting practices
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.MarketBeat
- Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.MarketBeat
STOK
Earnings
- 3/16/26 - Beat
STOK
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/27/26 - Form 8-K
- STOK's page on the SEC website